KarXT is an investigational medication being studied for treating agitation in people with Alzheimer’s disease. It works by targeting specific brain receptors that may help control agitated behaviors and symptoms that are common in Alzheimer’s patients.

KarX-EC is a supplementary medication used in combination with KarXT. It is being studied to understand how well these medications work together for long-term treatment of agitation symptoms in people with Alzheimer’s disease.

Agitation Associated with Alzheimer’s Disease – A behavioral symptom that commonly occurs in people who have Alzheimer’s disease, characterized by excessive psychomotor activity, emotional lability, and a heightened state of arousal. Patients may display restlessness, pacing, verbal aggression, and physical aggression. The condition tends to fluctuate throughout the day and often worsens in the late afternoon or evening. It typically develops as Alzheimer’s disease progresses and can significantly impact daily activities and social interactions. The agitation may be triggered by environmental changes, confusion, or inability to communicate effectively.

Alzheimer’s Disease – A progressive brain disorder that slowly destroys memory, thinking skills, and the ability to carry out simple tasks. The disease begins with mild memory loss and confusion, gradually affecting various cognitive functions. Brain changes typically start years before the first symptoms appear. As the disease advances, individuals experience increasing difficulty with communication, reasoning, and judgment. The condition affects different parts of the brain, leading to various cognitive and behavioral changes over time.